News

Claire’s Place Foundation, a nonprofit supporting cystic fibrosis (CF) patients and their families, has launched the LA Fire Emergency Fund to help people with CF who are affected by the wildfires that have broken out this month in southern California. This temporary financial assistance program — being…

Prenatal Trikafta treatment of three fetuses with cystic fibrosis (CF) for an intestinal blockage called meconium ileus resulted in different outcomes, potentially due to treatment duration, according to a case series. One infant showed a complete resolution of meconium ileus at birth, one had persistent signs that were…

People with cystic fibrosis (CF) saw sustained reductions in the use of several other CF therapies after two years of treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor), with airway medications and antibiotics being the most reduced, according to a real-world study from Denmark. “This study adds evidence of the real-world impact…

Registration is now open for BreatheCon 2025, an annual online event hosted by the Cystic Fibrosis Foundation that aims to foster connections between adults with cystic fibrosis (CF). This year’s BreatheCon will take place Feb. 7-8. Registration and additional information about the virtual event is available on the…

Claire’s Place Foundation, a nonprofit supporting children and families affected by cystic fibrosis (CF), has launched a CF Ambassador & Advisory program — and is now seeking to grow the new initiative. By involving advocates and people living with CF in the foundation’s mission, and amplifying patient voices…

After one year of treatment with Kaftrio, a triple combination of elexacaftor, tezacaftor, and ivacaftor marketed as Trikafta in the U.S., the number of harmful bacteria growing in the lungs of people with cystic fibrosis (CF) declined significantly, a French study reports. “We observed a significant decrease in…

A Phase 1b trial assessing the safety of RCT2100, Recode Therapeutics’ inhaled therapy candidate for people with cystic fibrosis (CF), has now dosed its first patient in the U.S. The trial already was underway in Europe. RCT2100 is being developed for patients who do not respond to or…

Dosing has begun in a Phase 2 clinical study testing ARCT-032, an experimental inhaled treatment Arcturus Therapeutics is developing for cystic fibrosis (CF) patients, including those who don’t benefit from CFTR modulators. The LunairCF study (NCT06747858) is recruiting adults with a diagnosis of CF who are…

Acceptance and commitment therapy (ACT), which helps people accept feelings and adjust behavior, was better than supportive psychotherapy for adults with cystic fibrosis (CF) facing mental health challenges, a small study found. In the trial (NCT04114227) sponsored by Thomas Jefferson University in Philadelphia and with sessions conducted online,…

The U.S. Food and Drug Administration (FDA) has expanded the approval of Trikafta for people with cystic fibrosis (CF) ages 2 and older who carry certain mutations that are responsive to the medication. With the approval, 94 additional non-F508del CFTR mutations have been added to the medication’s label,…